AdultPediatricGeriatricDosage Forms & Strengths tablet 10mg 20mg 30mg 40mg capsule 7.5mg tablet, extended-release 12.5mg 25mg 37.5mg oral suspension 10mg/5mL Depression Conventional: 20 mg PO qDay initially; may increase by 10 mg/day qWeek not to exceed 50 mg/day Paxil CR: 25 mg PO qDay initially; may increase by 12.5 mg/day qWeek not to exceed 62.5 mg/day Obsessive-Compulsive Disorder 20 mg PO qDay initially; may increase by 10 mg qWeek, not to exceed 60 mg/day Panic Disorder 10 mg PO qDay initially; may increase by 10 mg qWeek (target dose 40 mg/day), not to exceed 60 mg/day, OR Paxil CR: 12.5 mg PO qDay initial, increase by 12.5 mg qWeek not to exceed 75 mg/day Social Phobia 20 mg PO qDay OR Paxil CR: 12.5 mg PO qDay initially; may increase by 12.5 mg qWeek, not to exceed 37.5 mg/day Generalized Anxiety Disorder 20 mg PO qDay initially, may increase by 10 mg qWeek, up to 50 mg/day doses have been used but no increase in benefit seen at doses >20 mg/day Posttraumatic Stress Disorder 20 mg PO qDay initially; may increase by 10 mg qWeek, up to 50 mg/day doses have been used but no increase in benefit seen at doses >20 mg/day Premenstrual Dysphoric Disorder Paxil CR: 12.5 mg PO qDay initially; may increase at 1 week intervals not to exceed 25 mg/day Menopausal Vasomotor Symptoms Brisdelle: Indicated to treat moderate-to-severe vasomotor symptoms associated with menopause Brisdelle: 7.5 mg PO qHS Paxil CR (Off-label): 12.5-25 mg PO qDay Dosing Modifications Severe renal impairment (CrCl <30 mL/min) Conventional: 10 mg PO qDay initially; may titrate; not to exceed 40 mg/day Paxil CR: 12.5 mg PO qDay initially; may titrate; not to exceed 50 mg/day Stuttering (Off-label) 20 mg PO qDay Vasovagal Syncope (Off-label) 20 mg/day PO Diabetic Neuropathy (Off-label) 10 mg/day PO initially; may increase to 20-60 mg/daySafety and efficacy not establishedCaution should be used in the elderly because paroxetine is the most sedating and anticholinergic of the selective serotonin reuptake inhibitors The elderly are prone to SSRI/SNRI-induced hyponatremia; monitor closelyInteraction CheckerEnter a drug name and paroxetineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (9)eliglustatparoxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.fezolinetantparoxetine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsisocarboxazidisocarboxazid and paroxetine both increase serotonin levels. Contraindicated.phenelzinephenelzine and paroxetine both increase serotonin levels. Contraindicated.pimozideparoxetine increases levels of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Contraindicated. Coadministration increases pimozide AUC and Cmax and may result in prolonged QT interval.procarbazineprocarbazine and paroxetine both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.selegilineselegiline and paroxetine both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.thioridazineparoxetine increases levels of thioridazine by decreasing metabolism. Contraindicated. Risk of long QT syndrome.tranylcyprominetranylcypromine and paroxetine both increase serotonin levels. Contraindicated.Serious - Use Alternative (100)alfentanilalfentanil, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.amiodaroneamiodarone and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.amitriptylineparoxetine and amitriptyline both increase serotonin levels. Avoid or Use Alternate Drug.amoxapineparoxetine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.aripiprazoleparoxetine will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.arsenic trioxidearsenic trioxide and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.asenapineasenapine and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.bupropionbupropion will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible.buspironeparoxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.carvedilolparoxetine will increase the level or effect of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.chlorpromazineparoxetine will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.citalopramcitalopram and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.clomipramineparoxetine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.cyclobenzaprineparoxetine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. desipramineparoxetine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.desvenlafaxineparoxetine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.dextromethorphanparoxetine will increase the level or effect of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.disopyramidedisopyramide and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.dolasetrondolasetron, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.dosulepinparoxetine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepinparoxetine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.duloxetineparoxetine will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.duloxetine and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.eliglustateliglustat and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.escitalopramescitalopram and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.fedratinibparoxetine will increase the level or effect of fedratinib by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied.fentanylfentanyl, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl intranasalfentanyl intranasal, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transdermalfentanyl transdermal, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transmucosalfentanyl transmucosal, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.flecainideparoxetine will increase the level or effect of flecainide by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluoxetinefluoxetine will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluoxetine and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.fluphenazineparoxetine will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluphenazine and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.fluvoxaminefluvoxamine and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.gilteritinibgilteritinib will decrease the level or effect of paroxetine by Other (see comment). Avoid or Use Alternate Drug. Coadministration of gilteritinib with drugs that inhibit 5HT2B or sigma nonspecific receptors. Avoid use of these drugs with gilteritinib unless coadministration is necessary.gilteritinib and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.granisetrongranisetron, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.granisetron and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.haloperidolparoxetine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.hydromorphoneparoxetine will increase the level or effect of hydromorphone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.hydromorphone, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.ibutilideibutilide and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.iloperidoneparoxetine will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.imipramineparoxetine will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.indapamideindapamide and paroxetine both increase QTc interval. Avoid or Use Alternate Drug.levomilnacipranlevomilnacipran and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.linezolidlinezolid and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.lofepramineparoxetine will increase the level or effect of lofepramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug.lonafarnibparoxetine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.lorcaserinparoxetine and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.maprotilineparoxetine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.mefloquinemefloquine increases toxicity of paroxetine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.meperidineparoxetine and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.meperidine, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.methamphetamineparoxetine will increase the level or effect of methamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.methylene bluemethylene blue and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.metoclopramidemetoclopramide and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactionsmetoclopramide intranasalparoxetine will increase the level or effect of metoclopramide intranasal by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of metoclopramide intranasal and strong CYP2D6 inhibitors is not recommended since the metoclopramide intranasal dose cannot be adjusted.paroxetine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.metoprololparoxetine will increase the level or effect of metoprolol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.mexiletineparoxetine will increase the level or effect of mexiletine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.milnacipranmilnacipran and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.morphineparoxetine will increase the level or effect of morphine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.morphine, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.nebivololparoxetine will increase the level or effect of nebivolol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.nefazodonenefazodone and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.netupitant/palonosetronnetupitant/palonosetron, paroxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.nortriptylineparoxetine will increase the level or